The HIV-1 protease is becoming the focus of intense study both as a key enzyme in the life cycle of HIV-1 and as a critical target for the development of an effective antiviral. The protease plays a central role during virion assembly as it cleaves the viral Gag and Gag/Pol precursors. Ordered and near complete cleavage of these precursor proteins is required for the efficient budding of virus particles and the formation of infectious virions. This central role in the virus life cycle makes the protease a biologically important protein, and its small size and well characterized catalytic activity make it amenable to a variety of biochemical analyses. In addition, it is possible to do structural analysis of the protease, making all of the major tools for protein characterization available for the study of the viral protease. We currently have a library of over 500 characterized protease mutants, and this library is the starting point for selecting mutants for further detailed study. In addition, experimental approaches are available to study the protease as a model for protein evolution, and to study the role of and control of ordered processing of the viral precursor proteins during particle assembly. Taken together, these studies provide fundamental insights into the molecular details of protein function for this critical viral protein. Specifically, I propose the following: i) Extend our ongoing structure-function analysis of the HIV-1 protease, focusing on issues of substrate specificity, protein stability, and structure determination; ii) Examine how protease sequences are evolving in the different clades of HIV-1 and the role of compensatory mutations in fixing sequence changes; iii) Explore the role of ordered processing of the Gag and Gag/Pol precursors during virion assembly and the determinants that regulate ordered processing.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI025321-11
Application #
2429377
Study Section
AIDS and Related Research Study Section 3 (ARRC)
Project Start
1987-09-30
Project End
2000-05-31
Budget Start
1997-06-01
Budget End
1998-05-31
Support Year
11
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Resch, Wolfgang; Parkin, Neil; Watkins, Terri et al. (2005) Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J Virol 79:10638-49
Watkins, Terri; Resch, Wolfgang; Irlbeck, David et al. (2003) Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 47:759-69
Resch, Wolfgang; Ziermann, Rainer; Parkin, Neil et al. (2002) Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor ab J Virol 76:8659-66
Pettit, Steve C; Henderson, Gavin J; Schiffer, Celia A et al. (2002) Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol 76:10226-33
Resch, W; Parkin, N; Stuelke, E L et al. (2001) A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc Natl Acad Sci U S A 98:176-81
Shehu-Xhilaga, M; Kraeusslich, H G; Pettit, S et al. (2001) Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation. J Virol 75:9156-64
Wrobel, J A; Conrad, M J; Bloedon, E et al. (2000) Analysis of HIV type 1 reverse transcriptase: comparing sequences of viral isolates with mutational data. AIDS Res Hum Retroviruses 16:2049-54
Vaillancourt, M; Irlbeck, D; Smith, T et al. (1999) The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance. AIDS Res Hum Retroviruses 15:355-63
Wrobel, J A; Chao, S F; Conrad, M J et al. (1998) A genetic approach for identifying critical residues in the fingers and palm subdomains of HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A 95:638-45
Pettit, S C; Sheng, N; Tritch, R et al. (1998) The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv Exp Med Biol 436:15-25

Showing the most recent 10 out of 24 publications